Form 4: Indaptus Therapeutics CSO Acquires 52,204 Shares

Indaptus Therapeutics' CSO and Director, Michael Newman, acquired 52,204 shares of common stock at $2.03 per share.

Summary

• Michael James Newman, the Chief Scientific Officer (CSO) and a Director of Indaptus Therapeutics, Inc. (INDP), acquired 52,204 shares of common stock.
• The transaction occurred on December 22, 2025, with shares priced at $2.03 each.
• This acquisition was made pursuant to an amendment to his employment agreement and in connection with a securities purchase agreement dated December 22, 2025.
• Following this transaction, Michael Newman directly beneficially owns a total of 101,074 shares of Indaptus Therapeutics common stock.

Sentiment

Score: 7

Explanation: The acquisition of shares by a key insider is generally a positive signal, indicating confidence in the company's future. However, as it's part of an employment agreement amendment rather than a purely open-market discretionary purchase, the signal is moderately positive.

Positives

• Insider acquisition of shares by a key executive (CSO) and Director can signal confidence in the company's future prospects.
• The acquisition increases the insider's direct beneficial ownership, aligning management's interests further with shareholders.

Future Outlook

NA

Industry Context

Insider buying, particularly by high-ranking executives and directors, is often viewed by the market as a positive indicator, suggesting that those with the most intimate knowledge of the company believe its stock is undervalued or has significant upside potential. This transaction aligns with general patterns of insider activity where executives increase their stake.

Related Party Transactions

• The acquisition of 52,204 shares of common stock by Michael Newman was pursuant to an amendment to his employment agreement and in connection with a securities purchase agreement, indicating a transaction directly between the company and an insider.

Stakeholder Impact

• Shareholders may perceive this insider purchase as a positive sign of management's belief in the company's value and future performance, potentially boosting investor confidence.
• Employees may see this as a sign of stability and commitment from leadership.

Key Dates

Recommendation

While insider buying is generally a positive indicator, this specific acquisition by Michael Newman was tied to an amendment to his employment agreement and a securities purchase agreement, rather than a purely discretionary open-market purchase. This context suggests a structured transaction rather than a spontaneous market-driven investment. Therefore, while it aligns management's interests with shareholders and signals confidence, it's not as strong a 'buy' signal as an unprompted open-market purchase might be. Investors should 'hold' and monitor further developments and broader company performance.

Keywords

Indaptus Therapeutics, INDP, Michael Newman, Insider Trading, Stock Acquisition, Form 4, Common Stock, CSO, Director